TMCnet News
Tauriga Sciences Inc. Plans Summertime Re-Launch of its Flagship Tauri-Gum Brand in the New York City Metropolitan Area MarketplaceThe Company has Established Relationships with Hundreds of Distinct NY Metro Area Retail Locations (i.e. Supermarkets, Delis, Kiosks, Specialty Grocers, Pharmacies, Smoke Shops, etc.) NEW YORK, NY, June 05, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with proprietary CBD & CBG infused chewing gums and edibles product(s) as well as two ongoing Biotechnology initiatives, today announced its planned Summertime re-launch of its flagship Tauri-Gum™ brand in the New York City Metropolitan area (“NY Metro”) retail marketplace. Recall that during the spring of 2019, the Company successfully launched its Mint Flavor Tauri-Gum™ product (CBD Infused) in the NY Metro area marketplace. Due to a subsequent ruling by the New York City Council (applicable to the entire CBD edibles sector), the Company was forced to withdraw from the NYC Metro market. The Company has recently disclosed its Immune Booster version of Tauri-Gum™ (Pear Bellini Flavor), which contains NO Phytocannabinoids. Each piece of Immune Booster Tauri-Gum™ chewing gum contains 60mg Vitamin C & 10mg Elemental Zinc. Therefore, it is perfectly legal to sell this product version, in the NY Metro area retail marketplace. With access to its previously established relationships in the NY Metro area, the Company has decided to re-launch its flagship Tauri-Gum™ brand during this upcoming Summer. Should the NYC City Council ultimately lift the CBD Edibles ban, the Company will have an existing infrastructure in place, to efficiently and effectively capitalize. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranae) & (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon and Black Currant). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives. The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity. The Company is headquartered in New York City and operates a regional office in Barcelona, Spain. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York. DISCLAIMER -- Forward-Looking Statements Contact: CONTACT INFORMATION Attachment |